ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology

 ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology

ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology

Shots:

  • Adagene to receive upfront, development & commercial milestones, research funding and royalties on sales with certain commercialization rights for Greater China.  ADC Therapeutics to utilize Adagene’s SAFEbody technology generating Abs that will further combine with its pyrrolobenzodiazepine (PBD) cytotoxic payload technology to develop masked ADCs for solid tumors
  • ADC Therapeutics also has an option to utilize SAFEbody technology for one additional exclusive target. The programs will focus on the targets in which healthy tissue expression prevent the development of ADCs
  • SAFEbody technology produces masked ADCs that binds with an antigen in tumor tissues only enhancing the specificity of an ADC with minimization in off-target toxicity on healthy cells

Click here to read full press release/ article | Ref: ADC Therapeutics | Image: ADCReview

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post